Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.30 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31483929 | 0.81 | MEN1 (0.45) | MEN1KMT2AALDH1A1RAB9APPARG | |
| SCHEMBL6169768 | 0.81 | MEN1 (0.47) | MEN1KMT2AALDH1A1RAB9AKDM4E | |
| SCHEMBL29439804 | 0.81 | NPSR1 (0.44) | MEN1KMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL22715645 | 0.81 | NPSR1 (0.44) | MEN1KMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6169849 | 0.78 | MEN1 (0.53) | MEN1KMT2AALDH1A1KDM4EMAPK1 | |
| SCHEMBL3282837 | 0.74 | PPARG (0.45) | MEN1KMT2AALDH1A1KDM4EMAPK1 | |
| SCHEMBL22715408 | 0.73 | HPGD (0.40) | MEN1KMT2AALDH1A1RAB9AKDM4E | |
| SCHEMBL29248881 | 0.72 | LMNA (0.46) | ALDH1A1RAB9AAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL16963172 | 0.72 | MEN1 (0.46) | MEN1KMT2AALDH1A1KDM4EMAPK1 | |
| SCHEMBL14007696 | 0.69 | RAB9A (0.36) | MEN1KMT2AALDH1A1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| EP-4522608-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023217906-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| US-9062043-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES, INC. (TW) | 2015-06-23 | — | — | US | disclosed |
| EP-2061765-B1 | Serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES INC (TW) | 2014-10-22 | — | — | EP | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| EP-2419101-A2 | METHOD OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY | Cylene Pharmaceuticals, Inc. (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20110263581-A1 | FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7956064-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| WO-2010121225-A2 | METHOD OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY | CYLENE PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267753-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY | SENHWA BIOSCIENCES, INC. (TW) | 2010-10-21 | — | — | US | disclosed |
| US-20090264423-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| WO-2009108912-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009097014-A2 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| EP-2061765-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | Cylene Pharmaceuticals, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263581-A1 | FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PARP1, PARP11, TNKS | MEN1 3970/4885KMT2A 1417/4885ALDH1A1 3612/4885 |
| US-20100267753-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY | CSNK2A1, CSNK2A2, CSNK2B | MEN1 2818/4885KMT2A 1107/4885ALDH1A1 4559/4885 |
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | MEN1 3699/4885KMT2A 2867/4885ALDH1A1 4167/4885 |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | PACSIN2, CKS1B, CSNK1A1 | MEN1 4148/4885KMT2A 1305/4885ALDH1A1 4513/4885 |
| US-20090264423-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PACSIN2, TNKS, PARP1 | MEN1 4111/4885KMT2A 1210/4885ALDH1A1 3529/4885 |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | MEN1 3739/4885KMT2A 1381/4885ALDH1A1 3801/4885 |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PACSIN2, TNKS, PARP1 | MEN1 4111/4885KMT2A 1210/4885ALDH1A1 3529/4885 |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | MEN1 3739/4885KMT2A 1381/4885ALDH1A1 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.